

# **POSTER PRESENTATION**

Open Access

# PreImplantation factor (PIF) potentiates static magnetic field (SMF) effect to decrease tumor burden (melanoma murine model)

Beatrix Kotlan<sup>1,2\*</sup>, Janos F Laszlo<sup>3</sup>, Jozsef Tovari<sup>4</sup>, Miklos Kasler<sup>5,6</sup>, Eytan Barnea<sup>7,8</sup>

From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013

## **Background and objectives**

PreImplantation factor (PIF) secreted by viable embryos exerts essential regulatory role on global systemic immune response. Synthetic PIF (PIF) translates endogenous effects to immune disorder models. Metastatic melanoma displays tumor-immunological behaviour. Static magnetic field (SMF) affects inflammatory reactions. There is increased interest toward SMF's potential antitumor effects. Herein examined a novel anti-melanoma strategy using combined physical and immune-based therapy.

### **Methods**

Daily whole-body SMF exposure, combined with subcutaneous PIF administration was examined in engrafted HT199 melanoma cells' progression, transplanted into NSG mice. PIF effect on unique tumor-associated antigen expression relevant for tumor proliferation/ invasion was examined in vitro using specific antibodies. Direct PIF anti-proliferative effects on several cancer cell lines were tested using MTT.

### **Results**

PIF potentiates SMF beneficial effect by reducing tumor volume vs. control (Mmax=96%) on day 34. Metastatic spleen mass is reduced by SMF alone (M=59%) or combined with PIF (M=62%). Daily SMF exposure alone inhibits tumor outgrowth (Mmax=60%, F5.32 (P<0.002) =21.16) while in combination with PIF, effect is considerably potentiated (M=80%), F5.32(P<0.0004)=34.84). PIF did not impair tumor antigen expression nor reduced significantly cultured tumor cell lines' proliferation.

<sup>1</sup>Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary

Full list of author information is available at the end of the article

### **Conclusions**

Collectively, results indicate that PIF's potentiating antitumoral effect is mainly immune-regulatory, synergizing with SMF's pro-tumor necrosis properties. The preserved tumor-associated antigen expression is important for the maintained antitumor immune activity. Overall, combined physico / immune regulatory treatment represents a useful, promising novel avenue for anti-cancer strategy.

### Acknowledgments

Harry J Loyd Charitable Trust Melanoma Research Award, INNO 08-3-2009-0248, BioIncept LLC - PIF proprietary.

### Authors' details

<sup>1</sup>Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary. <sup>2</sup>Surgical and Molecular Tumorpathology, National Institute of Oncology, Budapest, Hungary. <sup>3</sup>Applied Mathematics and Probability Theory, University of Debrecen, Faculty of Informatics, Debrecen, Hungary. <sup>4</sup>Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary. <sup>5</sup>Board of Directors, National Institute of Oncology, Budapest, Hungary. <sup>6</sup>Univ Medicine and Pharmacy, Tirgu Mures, Romania. <sup>7</sup>Society for the Investigation of Early Pregnancy, Cherry Hill, NJ, USA. <sup>8</sup>BioIncept LLC, Cherry Hill, NJ, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P80

Cite this article as: Kotlan *et al.*: PreImplantation factor (PIF) potentiates static magnetic field (SMF) effect to decrease tumor burden (melanoma murine model). *Journal for ImmunoTherapy of Cancer* 2013 1(Suppl 1):P80.

